Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)-Reference-Cited by-同舟云学术

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)

Published:2017-09-08 Issue:43 Volume:8 Page:75217-75231
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Jochems Caroline¹,Tritsch Sarah R.¹,Pellom Samuel Troy¹,Su Zhen²,Soon-Shiong Patrick³,Wong Hing C.⁴,Gulley James L.⁵,Schlom Jeffrey¹

Affiliation:

1. Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

2. EMD Serono, Rockland, MA, USA

3. NantWorks, Culver City, CA, USA

4. Altor BioScience Corporation, Miramar, FL, USA

5. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies;ACS Omega;2024-08-23

2. Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective;Pharmaceuticals;2024-04-20

3. A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma;Leukemia & Lymphoma;2024-03-09

4. The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer;Frontiers in Oncology;2024-01-04

5. Applications of biomimetic nanoparticles in breast cancer as a blueprint for improved next-generation cervical cancer therapy;Nano Today;2023-12